Study links GLP1 agonists to reduced risk of severe liver disease in diabetic patients

Ozempic and other GLP1 agonists are associated with a reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes and chronic liver disease, according to a nationwide study from Karolinska Institutet in Sweden published in the journal Gut.

Pivoting to ‘ADC-like’ approach, Versant-backed startup gets $90M Series C

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

June 12, 2024

Dementia Linked With Depression in Early and Middle Life

Depression diagnosed in early, middle, or late life more than doubled the risk for subsequent dementia, a study of 1.4 million people in Denmark showed.

July 25, 2023

BIO, PhRMA press FDA for concrete details on new IT strategy

After the FDA unveiled its overarching IT strategy earlier this fall, lobbying groups like BIO and PhRMA, as well as tech giant Google, are asking

November 4, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.